Inloggad som:

MK6482-005

Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.

MK6482-005
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies
An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD- 1/L1 and VEGF-Targeted Therapies
PLACEHOLDER
Mer information om studien för vårdgivare
Behandling
Fas 3
Palliativ
Företag

Studien ändrades senast av: studyjohanna (2021-07-13)

Tillbaka till listan